Researcher.Life Logo

Pulmonary Pharmacology and Therapeutics : Impact Factor & More

eISSN: 1522-9629pISSN: 1094-5539

Aims and Scope of Pulmonary Pharmacology and Therapeutics

Pulmonary Pharmacology & Therapeutics is a medical journal published by Elsevier that covers research on the pharmacotherapy of lung diseases. It was established in 1988 as Pulmonary Pharmacology and obtained its current title in 1997. Less

Key Metrics

CiteScore
5.8
H-Index
78
Impact Factor
< 5
SJR
Q2Biochemistry (medical)
SNIP
0.84
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Pulmonary Pharmacology and Therapeutics

Pulmonary Pharmacology and Therapeutics Journal Specifications

Overview
Publisher ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1988
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Pulmonary Pharmacology and Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Pulmonary Pharmacology and Therapeutics

Nicotinamide N-oxide alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through activation of the SIRT1/AKT signalling pathway.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients.
  • 10 Mar 2026
  • Pulmonary pharmacology & therapeutics
Targeting ELK-1 transcription factor and mechanosensitive MDM4 receptor using an HCN channel blocker alleviates lung fibrosis.
  • 1 Mar 2026
  • Pulmonary pharmacology & therapeutics
Effectiveness of Mepolizumab and Dupilumab in Patients with Asthma-COPD Overlap (ACO) compared to Severe Uncontrolled Asthma: A Retrospective Observational Cohort Study.
  • 1 Mar 2026
  • Pulmonary pharmacology & therapeutics
Nicotinamide N-oxide alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through activation of the SIRT1/AKT signalling pathway.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial.
  • 1 Jun 2026
  • Pulmonary pharmacology & therapeutics
Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients.
  • 10 Mar 2026
  • Pulmonary pharmacology & therapeutics
Targeting ELK-1 transcription factor and mechanosensitive MDM4 receptor using an HCN channel blocker alleviates lung fibrosis.
  • 1 Mar 2026
  • Pulmonary pharmacology & therapeutics
Effectiveness of Mepolizumab and Dupilumab in Patients with Asthma-COPD Overlap (ACO) compared to Severe Uncontrolled Asthma: A Retrospective Observational Cohort Study.
  • 1 Mar 2026
  • Pulmonary pharmacology & therapeutics

FAQs on Pulmonary Pharmacology and Therapeutics